Schizophrenia

Top Story

Teva recalls extended-release paliperidone due to dissolution failure

June 16, 2017

Teva Pharmaceuticals recently announced a voluntary recall on one lot of 90-count, 3-mg bottles of paliperidone extended-release tablets to retail and consumers.

The recalled lot is number 1160682A, NDC 0591-3693-19, with a June 2018 expiration, distributed under the Actavis Pharma Inc. label between Dec. 12, 2016 and March 16, 2017.

In the Journals

Adolescent personality plays role in risk for adult mental illness

June 16, 2017
Nationwide study results indicated low social maturity, mental energy and emotional stability in late adolescence were associated with subsequent psychiatric disorders…
In the Journals

Good response rare for antipsychotics in acute schizophrenia

June 13, 2017
Analysis of 60 years of placebo-controlled antipsychotic drug trials indicated approximately twice as many individuals with acute schizophrenia improved with…
In the Journals

Recovery-oriented cognitive therapy has long-term benefits for schizophrenia

June 8, 2017
Recovery-oriented cognitive therapy improved functioning in schizophrenia, notably among individuals with higher chronic illness. To assess the impact of…
CME

Comorbidities in Schizophrenia: Challenges for Researchers and Clinicians

Psychiatric Annals, October 2013, Volume 43 Issue 10
1. Provide strategies for combining psychotropics in treating persons with schizophrenia plus other psychiatric…
More »
CME

First-Episode Psychosis: November 2015

Keck School of Medicine of USC and Psychiatric Annals

Psychosis occurs first in young people and then can progress into a chronic lifelong disorder. Although some patients…
More »
Featured
American Psychiatric Association Annual Meeting

American Psychiatric Association Annual Meeting

Video
Meeting News Coverage

VIDEO: Recently approved Nuplazid fills treatment gap in Parkinson’s disease

May 25, 2016
More »
FDA News

Teva recalls extended-release paliperidone due to dissolution failure

June 16, 2017
Teva Pharmaceuticals recently announced a voluntary recall on one lot of 90-count, 3-mg bottles of paliperidone extended-release tablets to retail…

In the Journals

Adolescent personality plays role in risk for adult mental illness

June 16, 2017
Nationwide study results indicated low social maturity, mental energy and emotional stability in late adolescence were associated with subsequent…

In the Journals

Good response rare for antipsychotics in acute schizophrenia

June 13, 2017
Analysis of 60 years of placebo-controlled antipsychotic drug trials indicated approximately twice as many individuals with acute schizophrenia…

In the Journals

Recovery-oriented cognitive therapy has long-term benefits for schizophrenia

June 8, 2017
Recovery-oriented cognitive therapy improved functioning in schizophrenia, notably among individuals with higher chronic illness. To assess the…

In the Journals

Long-acting injectable antipsychotics best for relapse in schizophrenia

June 7, 2017
Long-acting injectable antipsychotic medications and clozapine were associated with highest rates of prevention of relapse in schizophrenia…

FDA News

FDA approves 2-month dosing option of Aristada for schizophrenia

June 6, 2017
The FDA today approved 2-month Aristada, an extended-release injectable suspension, to treat schizophrenia. “We designed Aristada to offer…

Meeting News

Long-term data shows efficacy, safety of valbenazine for tardive dyskinesia

June 2, 2017
SAN DIEGO — Data showing long-term efficacy and pharmacokinetic profile of Ingrezza capsules, recently approved by the FDA for treatment of…

CNE

Journal of Psychosocial Nursing and Mental Health Services June 2017 CNE Activity

June 1, 2017 Expires: 5/31/2019
Topics include perinatal anxiety and depression, perceived stress in family caregivers of individuals with mental illness, and public stigma toward…

This activity is co-provided by Villanova University College of Nursing and SLACK Incorporated.

Meeting News

Understand the early characteristics of tardive dyskinesia, instead of ignoring them

May 24, 2017
SAN DIEGO — Psychiatrists for too long have had a “desire to not be aware of the problem” of tardive dyskinesia, according a…

Meeting News

Prescription of second-generation, lower metabolic risk antipsychotics increases

May 21, 2017
SAN DIEGO — Findings presented here indicated that prescription of second-generation antipsychotics with lower metabolic risk have increased…

More Headlines »
Advertisement
Advertisement